WHO Prequalifies First Malaria Drug for Newborns, Infants
The World Health Organization has prequalified Coartem® Baby, the first malaria treatment specifically formulated for newborns and young infants weighing 2-5 kg. This crucial development by Novartis and Medicines for Malaria Venture addresses a significant treatment gap, promising safer and more effective care for the most vulnerable. It coincides with World Malaria Day, underscoring global efforts against the disease.
Key Highlights
- WHO prequalifies artemether-lumefantrine (Coartem Baby) for infants.
- First malaria treatment specifically designed for newborns 2-5 kg.
- Addresses long-standing treatment gap, reducing dosing errors.
- Novartis making drug available on not-for-profit basis.
- Prequalification enables global procurement and wider access.
- Malaria remains major threat, especially for young African children.
The World Health Organization (WHO) has marked a significant milestone in the global fight against malaria by prequalifying the first-ever malaria treatment developed specifically for newborns and young infants. Announced on April 24, 2026, ahead of World Malaria Day, this groundbreaking development pertains to a new formulation of artemether-lumefantrine, known commercially as Coartem® Baby or Riamet® Baby, which is tailored for infants weighing between 2 and 5 kilograms.
Until this prequalification, healthcare providers faced considerable challenges in treating the youngest malaria patients. Infants in this critical weight range were often administered formulations intended for older children, which posed a heightened risk of dosing inaccuracies, adverse side effects, and potential toxicity. This new, precise formulation effectively closes a long-standing treatment gap, ensuring that these highly vulnerable patients receive appropriate and safer care.
The prequalification status granted by the WHO is a critical step. It signifies that the medicine meets stringent international standards of quality, safety, and efficacy. This designation is essential for expanding access, as it enables United Nations agencies, such as UNICEF, and other public sector procurement bodies to purchase and distribute the drug globally, particularly in malaria-endemic regions. Without this prequalification, countries, especially those lacking robust regulatory systems, would find it challenging to authorize and deploy such a vital treatment.
Coartem® Baby was developed by pharmaceutical giant Novartis in collaboration with the Medicines for Malaria Venture (MMV). Novartis has committed to making this treatment available on a largely not-for-profit basis in regions severely affected by malaria, underscoring a dedication to global health equity. The introduction of this specialized treatment is expected to have a profound impact, particularly in Africa, where nearly 30 million babies are born each year in malaria-endemic areas.
Malaria continues to be a devastating global health burden. According to the World Malaria Report 2025, there were an estimated 282 million cases and 610,000 deaths from malaria in 2024, representing an increase from the previous year. The vast majority of these cases and deaths, approximately 95%, occur in the African Region, with children under the age of five accounting for a staggering three-quarters of all malaria-related fatalities. These statistics highlight the urgent need for comprehensive and innovative tools to combat the disease.
The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, emphasized the transformative potential of such innovations, stating that for centuries, malaria has stolen children and hope, but with new vaccines, diagnostic tests, next-generation mosquito nets, and effective medicines, including those adapted for the youngest, the tide is turning. This treatment complements other recent advancements in malaria control, including the WHO's recommendations for two malaria vaccines: RTS,S/AS01 (in October 2021) and R21/Matrix-M (in October 2023). While vaccines offer prevention, this new prequalified drug provides a crucial therapeutic option for infants who contract the disease.
The relevance of this news for an Indian audience is significant, despite the treatment not being developed by an Indian entity (unlike the R21 vaccine, which involves the Serum Institute of India). India, too, bears a substantial burden of malaria, and advancements in global malaria treatment and prevention strategies directly influence national public health policies and access to life-saving medicines. The availability of a quality-assured, specialized treatment for infants could inform India's procurement and treatment guidelines, potentially improving outcomes for its own child population at risk of malaria. This development reinforces the global commitment to eradicating malaria, aligning with India's efforts to achieve its own elimination targets.
Ultimately, the WHO's prequalification of artemether-lumefantrine for newborns and young infants represents a pivotal advancement, ensuring that a previously underserved and extremely vulnerable patient group now has access to a safe, effective, and appropriately formulated antimalarial treatment. It is a critical component in the broader strategy to reduce child mortality and move closer to a malaria-free future.
Frequently Asked Questions
What is the significance of WHO prequalifying the first malaria treatment for infants?
The prequalification means that for the first time, a malaria treatment (artemether-lumefantrine, Coartem® Baby) has been specifically formulated and approved for newborns and young infants weighing 2-5 kg. This closes a critical treatment gap, as previously, infants were treated with drugs designed for older children, leading to potential dosing errors and risks of side effects.
When was this malaria treatment for infants prequalified by the WHO?
The World Health Organization announced the prequalification of this new treatment on April 24, 2026, just ahead of World Malaria Day.
Who developed this new malaria treatment, and how will it be made available?
The treatment, Coartem® Baby (artemether-lumefantrine), was developed by Novartis in collaboration with Medicines for Malaria Venture (MMV). Novartis has stated it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions.
How does this treatment differ from the recently recommended malaria vaccines?
This prequalified product is a *treatment* drug for infants who have already contracted malaria. Malaria vaccines (like RTS,S and R21/Matrix-M, recommended by WHO in 2021 and 2023 respectively) are *preventive* tools designed to protect children from getting the disease in the first place. Both are crucial in the comprehensive fight against malaria.
Why is this development particularly important for countries with a high malaria burden, like those in Africa and India?
Malaria disproportionately affects children under five, particularly in Africa, where millions of babies are born in endemic areas annually. This specific treatment addresses a major health inequity and will enable safer, more effective care, potentially saving countless young lives. For India, a country with a significant malaria burden, this global advancement could inform national treatment protocols and improve outcomes for at-risk infants.
